Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma has received a Japanese marketing approval for Irribow tablets 2.5 microgram and 5 micro gram for the diarrhea-predominant irritable bowel syndrome in male.
Subscribe to our email newsletter
Irribow is a serotonin 5-HT3 receptor antagonist discovered by Astellas. According to the company, Irribow improves abnormal defaecation associated with the acceleration of intestinal transit by inhibiting 5-HT3 receptor selectively. It is also said to improve visceral hypersensitivity by suppressing the transmission of intestinal nociception.
Astellas expects to provide a new option for irritable bowel syndrome (IBS) medication. The launch timing will be announced after it appears in the NHI drug price list.